SCHEMBL5326906

SCHEMBL5326906

NC(CCc1ccc2c(c1)CC=C2)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 2/20 0.49
GRIA1 P42261 1/20 0.49
GRIA2 P42262 1/20 0.49
GRIA3 P42263 1/20 0.49
GRIA4 P48058 1/20 0.49
GRIK2 Q13002 1/20 0.49
GRIK3 Q13003 1/20 0.49
SLC7A5 Q01650 3/20 0.37
PTGS1 P23219 2/20 0.37
KDM4E B2RXH2 1/20 0.37
USP2 O75604 1/20 0.37
EGFR P00533 1/20 0.37
LCK P06239 1/20 0.37
FYN P06241 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
ALOX15 P16050 1/20 0.37
HTR2A P28223 1/20 0.37
PTGS2 P35354 1/20 0.37
RECQL P46063 1/20 0.37
HIF1A Q16665 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5324384 0.89 GRIK1 (0.49) GRIK1GRIA1GRIA2GRIA3GRIA4
SCHEMBL5320539 0.86 SLC7A5 (0.53) GRIA2SLC7A5PTGS1KDM4EUSP2
SCHEMBL586035 0.78 FFAR1 (0.44)
SCHEMBL5319999 0.74 SLC7A5 (0.53) GRIA2SLC7A5PTGS1KDM4EUSP2
SCHEMBL585323 0.74 KDM4E (0.46) PTGS1KDM4EHIF1AHSD17B10TDP1
SCHEMBL5324757 0.72 GRIK1 (0.37) GRIK1GRIA1GRIA2GRIA3GRIA4
SCHEMBL5326842 0.72 GRIK1 (0.37) GRIK1GRIA1GRIA2GRIA3GRIA4
SCHEMBL5287328 0.71 KDM4E (0.70) GRIK1GRIA1GRIA2GRIA3GRIA4
SCHEMBL6911329 0.71 CNR1 (0.40) HTR2A
SCHEMBL27607891 0.70 GRIK1 (0.53) GRIK1GRIA1GRIA2GRIA3GRIA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070258899-A1 Diagnostic and therapeutic agents KARYON-CTT LTD (FI) 2007-11-08 US disclosed
WO-2007113385-A1 DIAGNOSTIC AND THERAPEUTIC AGENTS KARYON-CTT LTD (FI) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070258899-A1 Diagnostic and therapeutic agents YBX1, MLX, TPX2 GRIK1 4162/4885GRIA1 3993/4885GRIA2 4396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.